700-49-2 | 2-Fluoroadenine

Packsize	Purity	Availability	Price	Discounted Price
100mg	97%	in stock	$9.00	$6.00
250mg	97%	in stock	$11.00	$8.00
1g	97%	in stock	$14.00	$10.00
5g	97%	in stock	$55.00	$38.00

Description

• Catalog Number: AB44073
• Chemical Name: 2-Fluoroadenine
• CAS Number: 700-49-2
• Molecular Formula: C5H4FN5
• Molecular Weight: 153.1172
• MDL Number: MFCD01632749
• SMILES: Fc1nc(N)c2c(n1)nc[nH]2
• NSC Number: 27364

Computed Properties

• Complexity: 154
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• XLogP3: -0.1

Literature

• Aberrant cyclization affords a C-6 modified cyclic adenosine 5'-diphosphoribose analogue with biological activity in Jurkat T cells.

  Journal of medicinal chemistry 20120223

• Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

  Cancer gene therapy 20110601

• Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

  BMC cancer 20110101

• Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase.

  The Journal of biological chemistry 20091002

• Diastereocontrolled electrophilic fluorinations of 2-deoxyribonolactone: syntheses of all corresponding 2-deoxy-2-fluorolactones and 2'-deoxy-2'-fluoro-NAD+s.

  The Journal of organic chemistry 20090821

• A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090815

• Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine.

  Protein science : a publication of the Protein Society 20090501

• Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.

  PloS one 20090101

• Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.

  Journal of experimental & clinical cancer research : CR 20090101

• Key labeling technologies to tackle sizeable problems in RNA structural biology.

  International journal of molecular sciences 20080601

• Cloning and functional expression of a novel Gi protein-coupled receptor for adenine from mouse brain.

  Molecular pharmacology 20080201

• Prodrug converting enzyme gene delivery by L. monocytogenes.

  BMC cancer 20080101

• Comparison of gene targeting efficiencies in two mosses suggests that it is a conserved feature of Bryophyte transformation.

  Biotechnology letters 20071001

• [(3)H]Adenine is a suitable radioligand for the labeling of G protein-coupled adenine receptors but shows high affinity to bacterial contaminations in buffer solutions.

  Purinergic signalling 20070901

• Nicotinamide 2-fluoroadenine dinucleotide unmasks the NAD+ glycohydrolase activity of Aplysia californica adenosine 5'-diphosphate ribosyl cyclase.

  Biochemistry 20070403

• Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine.

  Nucleosides, nucleotides & nucleic acids 20060101

• Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells.

  Biochemical pharmacology 20050801

• Identification of a subversive substrate of Trichomonas vaginalis purine nucleoside phosphorylase and the crystal structure of the enzyme-substrate complex.

  The Journal of biological chemistry 20050610

• Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity.

  Bone marrow transplantation 20050501

• Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues.

  Molecular pharmacology 20050301

• Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer.

  Nucleosides, nucleotides & nucleic acids 20050101

• Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.

  Gene therapy 20041101

• Enzymatic synthesis and 19F NMR studies of 2-fluoroadenine-substituted RNA.

  Journal of the American Chemical Society 20040929

• Synthesis of 2',5'-dideoxy-2-fluoroadenosine and 2',5'-dideoxy-2,5'-difluoroadenosine: potent P-site inhibitors of adenylyl cyclase.

  Journal of medicinal chemistry 20040226

• Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.

  The journal of gene medicine 20040101

• Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.

  Bioorganic & medicinal chemistry letters 20031117

• Convenient synthesis of 2'-deoxy-2-fluoroadenosine from 2-fluoroadenine.

  Nucleosides, nucleotides & nucleic acids 20031001

• Synthesis of carbocyclic and acyclic nucleosides possessing 2-fluoroadenine derivatives and their inhibitory activities against Plasmodium falciparum SAH hydrolase.

  Nucleic acids research. Supplement (2001) 20030101

• Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide.

  Blood 20020701

• Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.

  Gene therapy 20020601

• Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010201